Relationship of side effects with types of COVID-19 vaccines
DOI:
https://doi.org/10.33448/rsd-v12i12.43849Keywords:
COVID-19; Vaccination; Pandemic; Virus; Epistemology.Abstract
The COVID-19 pandemic is an ongoing global health crisis caused by the spread of the SARS-CoV-2 virus, which was first identified in December 2019 in Wuhan, China. To analyze the main side effects reported by individuals after receiving the COVID-19 vaccines. For this study, the bibliographic research technique will be used, using bibliographic sources of the type of publications, found in articles and separate publications. The research is classified as bibliographic, as it is prepared based on already published material. The Pfizer-BioNTech and Moderna vaccines use messenger RNA (mRNA) and are highly effective against COVID-19, with mild side effects. AstraZeneca uses an adenovirus vector and has demonstrated efficacy, with rare cases of blood clots. Johnson & Johnson is a single dose and effective against severe cases, sharing common side effects. CoronaVac, inactivated, is effective in preventing serious cases, with similar side effects. All vaccines are safe, with differences in technologies and effectiveness. The choice depends on the availability and guidance of health authorities in the fight against COVID-19. In conclusion, the various COVID-19 vaccines play a vital role in containing the pandemic, sharing mild and temporary side effects. The choice of vaccine depends on availability and local public health guidelines, but all have been safe and effective in preventing serious cases, highlighting the importance of vaccination in individual and community protection.
References
Almufty, H. B., Mohammed, S. A., Abdullah, A. M., & Merza, M. A. (2021). Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. Diabetes & metabolic syndrome, 15(5), 102207. https://doi.org/10.1016/j.dsx.2021.102207
Altamimi, A., & Ahmed, A. E. (2020). Climate factors and incidence of Middle East respiratory syndrome coronavirus. Journal of infection and public health, 13(5), 704–708. https://doi.org/10.1016/j.jiph.2019.11.011
Beatty, A. L., Peyser, N. D., Butcher, X. E., Cocohoba, J. M., Lin, F., Olgin, J. E., Pletcher, M. J., & Marcus, G. M. (2021). Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination. JAMA network open, 4(12), e2140364. https://doi.org/10.1001/jamanetworkopen.2021.40364
Bee, G. R., Pinto, D. D., da Silva, A. C. C. A., Oliveira, T., & Arrigo, J. da S. (2022). Vacinas contra COVID-19 disponíveis no Brasil / Vaccines against COVID-19 available in Brazil. Brazilian Journal of Development, 8(1), 6246–6263. https://doi.org/10.34117/bjdv8n1-422
Brandão Francisco, J. M, Trogo, J. F., Sangenis, L. H. C., & Dias de Souza Filho, G. D. de S. F. (2022). Principais efeitos adversos das vacinas contra a Covid-19 na população de Valença-RJ. Revista Saber Digital, 15(2), e20221510. https://doi.org/10.24859/SaberDigital.2022v15n2.1326
Caddy S. (2020). Developing a vaccine for covid-19. BMJ (Clinical research ed.), 369, m1790. https://doi.org/10.1136/bmj.m1790
Camargo, B. L. A. A., Rubira, E. de A., Arruda, A. G. N., & Melo, L. de A. (2022). Vacina anti-covid-19: ação protetora supera a ocorrência de eventuais efeitos adversos. Revista Científica Da Faculdade De Educação E Meio Ambiente, 13(edespccs). Recuperado de https://revista.faema.edu.br/index.php/Revista-FAEMA/article/view/1160
Dhama, K., Nainu, F., Frediansyah, A., Yatoo, M. I., Mohapatra, R. K., Chakraborty, S., Zhou, H., Islam, M. R., Mamada, S. S., Kusuma, H. I., Rabaan, A. A., Alhumaid, S., Mutair, A. A., Iqhrammullah, M., Al-Tawfiq, J. A., Mohaini, M. A., Alsalman, A. J., Tuli, H. S., Chakraborty, C., & Harapan, H. (2023). Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies. Journal of infection and public health, 16(1), 4–14. https://doi.org/10.1016/j.jiph.2022.11.024
Fonseca, E. M. D., Shadlen, K. C., & Bastos, F. I. (2021). The politics of COVID-19 vaccination in middle-income countries: Lessons from Brazil. Social science & medicine (1982), 281, 114093. https://doi.org/10.1016/j.socscimed.2021.114093
Gil, A. C. (2017) Como elaborar projetos de pesquisa. (5a ed.). Atlas S.A.
Gomes e Costa, D. A., Sasaki, M., Mostardeiro, M. M., Carpinelli, C. C., Pereira, D. L., Saliba e Borges, P., Barros, R. C., de Moura, S. C., Almeida, A. L. S. L., & Yamaguti, A. (2022). Impacto de vacinação contra sarscov2 em pacientes hospitalizados por covid19 acima de 60 anos. The Brazilian Journal of Infectious Diseases, 26, 101800. https://doi.org/10.1016/j.bjid.2021.101800
Gonçalves, K. C. R., Assunção, L. C., Martins, N. G., & Ribas, L. G. A. (2023). Tecnologia, eficácia e efeitos adversos das vacinas para covid-19 disponíveis no Brasil. Revista Ibero-Americana De Humanidades, Ciências E Educação, 9(9), 1685–1696. https://doi.org/10.51891/rease.v9i9.11351
Gouvea, M. D. P. G., Rocha, W. P., Moulaz, I. R., Miossi, R., Gouveia, T. M., Thompson, B. P., Lança, K. E. M., Lacerda, B. S. D. P., Lacerda, G. C. C., Lenzi, J. P. G., Miossi, J. P. M., Rassele, M. L., Pimentel, F. D. C., Ramos, S. D. S., Forechi, L., Faé, F., Moulin, A. C. S., de Barros, A. P., Souza, B. O., Surlo, H. F., … & Valim, V. (2022). Eventos adversos às vacinas Coronavac e Astrazeneca em uma coorte de trabalhadores da saúde. The Brazilian Journal of Infectious Diseases, 26, 102028. https://doi.org/10.1016/j.bjid.2021.102028
Maranhão, R. de A. ., & Senhoras, E. M. . (2020). Orçamento de guerra no enfrentamento à covid-19: entre manobras parlamentares e batalhas políticas. Boletim De Conjuntura (BOCA), 2(6), 113–132. https://doi.org/10.5281/zenodo.3899492
Marks, P. W., Gruppuso, P. A., & Adashi, E. Y. (2023). Urgent Need for Next-Generation COVID-19 Vaccines. JAMA, 329(1), 19–20. https://doi.org/10.1001/jama.2022.22759
Meo, S. A., Bukhari, I. A., Akram, J., Meo, A. S., & Klonoff, D. C. (2021). COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. European review for medical and pharmacological sciences, 25(3), 1663–1669. https://doi.org/10.26355/eurrev_202102_24877
Mukherjee R. (2020). Global efforts on vaccines for COVID-19: Since, sooner or later, we all will catch the coronavirus. Journal of biosciences, 45(1), 68. https://doi.org/10.1007/s12038-020-00040-7
Mushtaq, H. A., Khedr, A., Koritala, T., Bartlett, B. N., Jain, N. K., & Khan, S. A. (2022). A review of adverse effects of COVID-19 vaccines. Le infezioni in medicina, 30(1), 1–10. https://doi.org/10.53854/liim-3001-1
Prado, P. R. D., Gimenes, F. R. E., Lima, M. V. M., Prado, V. B. D., Soares, C. P., & Amaral, T. L. M. (2021). Risk factors for death due to COVID-19, in the state of Acre, Brazil, 2020: a retrospective cohort study. Fatores de risco para óbito por COVID-19 no Acre, 2020: coorte retrospectiva. Epidemiologia e serviços de saúde: Revista do Sistema Unico de Saude do Brasil, 30(3), e2020676. https://doi.org/10.1590/S1679-49742021000300018
Rezeno, A. S.; & Lellis, I. B. R. (2021) Efeitos adversos da vacinação contra a Covid-19: o risco do desenvolvimento e a responsabilidade do fornecedor. Trabalho de Conclusão de Curso (Bacharelado em Direito) - Faculdade de Direito de Vitória, Vitória-ES.
Rief W. (2021). Fear of Adverse Effects and COVID-19 Vaccine Hesitancy: Recommendations of the Treatment Expectation Expert Group. JAMA Health Forum. 2021;2(4):e210804. doi:10.1001/jamahealthforum.2021.0804
Rocha, G C; & Ribeiro C L. (2022). Efeitos adversos da vacinação contra covid-19 na população de Guarapuava-PR. Trabalho de Conclusão de Curso. Centro Universitário Campo Real. Platform & workflow by OJS/PKP. https://www.repositorio.camporeal.edu.br/index.php/med/article/view/582 Acesso em: 17 out. 2023.
Santos et al. (s.d.). Avaliação dos efeitos adversos após imunização pela vacina Oxford-Astrazeneca (chadox1). Revista Interdisciplinar Ciências Médicas. 7(2), 41-25.
Senhoras, E. M. (2021). O campo de poder das vacinas na pandemia da covid-19. Boletim De Conjuntura (BOCA), 6(18), 110–121. https://doi.org/10.5281/zenodo.5009525
Silva et al (2023). Classificação de risco para transmissão de doenças imunopreveníveis em Minas Gerais, Brasil: dois anos desde o início da pandemia de COVID-19. Ciênc. Saúde Coletiva. 28 (03) 699-710. https://doi.org/10.1590/1413-81232023283.11192022
Silva Filho, P. S. da P., Silva, M. J. de S., Fortes Júnior, E. J., Rocha, M. M. L., Araujo, I. A., Carvalho, I. C. S. Esperandio, J. V. M., Vasconcelos, A. C. A. B., Pompeu, J. G. F., Campelo, V. E. S., Silveira Filho, E. R., Paiva, M. L. R. de, Carvalho, A. M., Guedes, J. J. S., Rodrigues, I. C. D. S. J., Valente, V. da S., Pires, A. S. de S., & Mesquita, G. V. (2021). Coronavirus vaccines (COVID-19; SARS-COV-2) in Brazil: an overview. Research, Society and Development, 10(8), e26310817189. https://doi.org/10.33448/rsd-v10i8.17189
Trougakos, I. P., Terpos, E., Alexopoulos, H., Politou, M., Paraskevis, D., Scorilas, A., Kastritis, E., Andreakos, E., & Dimopoulos, M. A. (2022). Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. Trends in molecular medicine, 28(7), 542–554. https://doi.org/10.1016/j.molmed.2022.04.007
Yamamoto, K. (2022). Adverse effects of COVID-19 vaccines and measures to prevent them. Virol J 19, 100. https://doi.org/10.1186/s12985-022-01831-0
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Delvanir Alves Bispo de Souza; Maria Caroline da Cunha Souza; Jonathan Jean Vilhaba
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
